Fundraising FoxAMR Action Fund — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Antabio is a clinical-stage biopharmaceutical company developing novel antibacterial treatments for drug-resistant, Gram-negative bacterial infections identified as critical priorities by the WHO and CDC, with a focus on life-threatening hospital-acquired infections.
BiotechHealthtech
Marc Lemonnier(Chief Executive Officer)inRienk Pypstra(Chief Medical Officer)Gordon Waldron(Chief Financial Officer)inMagdalena Zalacain(Chief Scientific Officer)in
Co-investorsBNP Paribas DéveloppementIRDI SORIDEC GestionOmnes Capital
Clinical-stage biotech developing next-generation polyene antifungals for life-threatening invasive fungal infections.
BiotechNew York, US
Kieren Marr(Executive Officer, Director)
BoardJim Flynn(Director)Jonathan Leff(Director)
Board seatMartin Heidecker· per SEC Form D
Co-investorsIllinois VenturesDeerfield Management Company
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.